Is tumor cell radiation resistance correlated with metastatic ability?
Authors
Suit, HAllam, A
Allalunis-Turner, J
Brock, W
Girinsky, T
Hill, S
Hunter, N
Milas, L
Pearcey, R
Peters, L
West, Catharine M L
Affiliation
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114.Issue Date
1994-04-01
Metadata
Show full item recordAbstract
Patients who experience local failure following radiation treatment of epithelial malignancies exhibit a substantially higher rate of distant metastasis than those patients who achieve permanent local control. This fact has raised concern that the local failure to control the primary/regional tumor may serve as a marker of a particularly malignant neoplasm, i.e., high metastatic activity and radiation resistance. If this were true, there would be no gains in survival by increasing the efficacy of treating the primary/regional disease because the new local controls would develop distant metastasis. To investigate this concept, the relationship between distant metastasis probability and tumor cell radiation resistance has been studied by examining laboratory and clinical data (in vitro and in vivo assays) from six collaborating centers. TCD50s (radiation dose which inactivates half of the irradiated tumors) and incidence of distant metastasis in mice with local control have been evaluated for 24 murine tumor systems. SF2s (surviving fraction after 2 Gy) were determined in vitro for cell lines from 8 human, 13 mouse, and 15 rat tumors/tumor sublines and the metastatic activity assessed after injection of the cells into syngeneic murine hosts and xenogenic hosts for the human tumors. SF2s of cells from carcinomas of the head/neck, cervix, and endometrium which were controlled locally by radiation +/- surgery from four centers were compared for those which did and those which did not metastasize. The total number of patients studied was 222. The cumulative distributions of SF2s of locally controlled tumors which did and did not metastasize were not different in each of the data sets. Similarly, there was no demonstrable relationship between TCD50s and metastatic frequency in local control mice. Furthermore, the SF2s of murine and human tumor cell lines did not track with metastatic activity. Radiation sensitivity of clinical and laboratory tumors did not correlate with metastatic activity in studies of data from six centers.Citation
Is tumor cell radiation resistance correlated with metastatic ability? 1994, 54 (7):1736-41 Cancer Res.Journal
Cancer ResearchPubMed ID
8137288Type
ArticleLanguage
enISSN
0008-5472Collections
Related articles
- Influence of cellular radiation sensitivity on local tumor control of human melanoma xenografts given fractionated radiation treatment.
- Authors: Rofstad EK
- Issue date: 1991 Sep 1
- Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
- Authors: Lawenda BD, Arnold MG, Tokarz VA, Silverstein JR, Busse PM, McIntyre JF, Deschler DG, Baldini EH, Kachnic LA
- Issue date: 2008 Nov
- The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
- Authors: Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K
- Issue date: 2005 Mar 15
- Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
- Authors: Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, Perez CA
- Issue date: 2001 Jun
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)